8:36 AM ET
8-K
Regulatory Approval
SAB Biotherapeutics Regulatory Approval
SAB Biotherapeutics announced that the FDA has granted Fast Track designation to SAB-142, a fully human anti-thymocyte immunoglobulin being developed for Stage 3 type 1 diabetes. The designation is intended to expedite the development and review of the immunotherapy, which is currently in a Phase 2b clinical trial. Topline data from the SAFEGUARD study is anticipated in the second half of 2027.